The difference between earlier and later insulin therapy in protective effect on beta-cell functio
Not Applicable
- Conditions
- T2 diabetes
- Registration Number
- JPRN-UMIN000021290
- Lead Sponsor
- Division of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 69
Inclusion Criteria
Not provided
Exclusion Criteria
A)Under 20 years old B)treatment insulin C)Under insulin treatment within 12 months D)Diabetic coma E)Dysautonomia F)Unconscious hypoglycemia G)Advanced retinopathy (preproliferative diabetic retinopathy / preproliferative diabetic retinopathy) H)Renal dysfunction (eGFR<30mL/min) I)Infection J)During treatment or treatment plan of malignant neoplasm K)Autoimmune disease L)Use of Steroid medicine and/or immunosuppressor M)Active liver disease (ALT or AST >100IU/L or total bilirubin level >2.5 mg/dL) N)Pregnant, possibility of pregnancy, nursing or hope to become pregnant during the study period O)In addition, principal investigator or researcher deems inappropriate as a target
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1. Change of insulin secretory capacity
- Secondary Outcome Measures
Name Time Method 2. Correlation between change of insulin secretory capacity and clinical background 3. The items related to insulin therapy 2-1.The ratio of subjects leaving insulin therapy 2-2.Period until leaving insulin therapy 2-3.Insulin dose in subjects continuing insulin 2-4.Frequency of hypoglycemia and change of body weight in subjects with insulin 4. Examination item only for subjects leaving insulin therapy